Hiroyuki Tao1, Toshiki Tanaka2,3, Kazunori Okabe2. 1. Division of Thoracic Surgery, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-kiwa, Ube, Yamaguchi, 755-0241, Japan. htao@yamaguchi-hosp.jp. 2. Division of Thoracic Surgery, National Hospital Organization Yamaguchi-Ube Medical Center, 685 Higashi-kiwa, Ube, Yamaguchi, 755-0241, Japan. 3. Division of Chest Surgery, Department of Surgery and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, 755-8505, Japan.
Abstract
PURPOSE: Doublecortin and CaM kinase-like-1 (DCLK1) regulates microtubule polymerization in migrating neurons. Recently, DCLK1 has been reported to act as an intestinal tumor stem cell marker and has been shown to be expressed in cancer cells and in the stroma of breast, colon, pancreatic, and prostate cancers. Here, we studied DCLK1 expression in non-small cell lung cancer (NSCLC) by immunohistochemistry in association with clinicopathological factors and patient prognosis. METHODS: DCLK1 expression was analyzed by immunohistochemical staining of surgical specimens from 232 patients with pathological stage I NSCLC, including 187 adenocarcinomas. Relationships between the expression status of DCLK1 and clinicopathological factors were examined. The impact of DCLK1 expression status and other clinicopathological factors on survival was evaluated by univariate and multivariate analyses. RESULTS: Thirty-three (14.2%) of 232 patients had DCLK1-positive cancer cells. DCLK1 was also expressed in the tumor stroma in most of the specimens and was significantly associated with DCLK1 expression in cancer cells. DCLK1-positive cancer cells were more common in non-adenocarcinoma tissues (44.4%) than in adenocarcinoma tissues (7.0%). Moreover, positive DCLK1 expression in cancer cells and stromal cells was correlated with a worse prognosis. Histological analyses revealed that the presence of DCLK1-positive cancer cells was an independent risk factor for poor prognosis in adenocarcinoma, but was not significantly associated with prognosis in non-adenocarcinoma. CONCLUSIONS: DCLK1 expression was observed in tumor cells in patients with pathological stage I NSCLC and was correlated with adverse prognosis, especially in patients with adenocarcinoma. DCLK1 may be a potential new therapeutic target.
PURPOSE:Doublecortin and CaM kinase-like-1 (DCLK1) regulates microtubule polymerization in migrating neurons. Recently, DCLK1 has been reported to act as an intestinal tumor stem cell marker and has been shown to be expressed in cancer cells and in the stroma of breast, colon, pancreatic, and prostate cancers. Here, we studied DCLK1 expression in non-small cell lung cancer (NSCLC) by immunohistochemistry in association with clinicopathological factors and patient prognosis. METHODS:DCLK1 expression was analyzed by immunohistochemical staining of surgical specimens from 232 patients with pathological stage I NSCLC, including 187 adenocarcinomas. Relationships between the expression status of DCLK1 and clinicopathological factors were examined. The impact of DCLK1 expression status and other clinicopathological factors on survival was evaluated by univariate and multivariate analyses. RESULTS: Thirty-three (14.2%) of 232 patients had DCLK1-positive cancer cells. DCLK1 was also expressed in the tumor stroma in most of the specimens and was significantly associated with DCLK1 expression in cancer cells. DCLK1-positive cancer cells were more common in non-adenocarcinoma tissues (44.4%) than in adenocarcinoma tissues (7.0%). Moreover, positive DCLK1 expression in cancer cells and stromal cells was correlated with a worse prognosis. Histological analyses revealed that the presence of DCLK1-positive cancer cells was an independent risk factor for poor prognosis in adenocarcinoma, but was not significantly associated with prognosis in non-adenocarcinoma. CONCLUSIONS:DCLK1 expression was observed in tumor cells in patients with pathological stage I NSCLC and was correlated with adverse prognosis, especially in patients with adenocarcinoma. DCLK1 may be a potential new therapeutic target.
Entities:
Keywords:
Doublecortin and CaM kinase-like-1 (DCLK1); Non-small cell lung cancer (NSCLC); Prognosis; Tumor stroma
Authors: Sripathi M Sureban; Randal May; Stan A Lightfoot; Aimee B Hoskins; Megan Lerner; Daniel J Brackett; Russell G Postier; Rama Ramanujam; Altaf Mohammed; Chinthalapally V Rao; James H Wyche; Shrikant Anant; Courtney W Houchen Journal: Cancer Res Date: 2011-02-01 Impact factor: 12.701
Authors: William D Travis; Elisabeth Brambilla; Andrew G Nicholson; Yasushi Yatabe; John H M Austin; Mary Beth Beasley; Lucian R Chirieac; Sanja Dacic; Edwina Duhig; Douglas B Flieder; Kim Geisinger; Fred R Hirsch; Yuichi Ishikawa; Keith M Kerr; Masayuki Noguchi; Giuseppe Pelosi; Charles A Powell; Ming Sound Tsao; Ignacio Wistuba Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Elizabeth A Sell; Jorge F Ortiz-Carpena; De'Broski R Herbert; Noam A Cohen Journal: Ann Allergy Asthma Immunol Date: 2020-10-26 Impact factor: 6.347
Authors: Michael A Kohanski; Alan D Workman; Neil N Patel; Li-Yin Hung; Julie P Shtraks; Bei Chen; Mariel Blasetti; Laurel Doghramji; David W Kennedy; Nithin D Adappa; James N Palmer; De'Broski R Herbert; Noam A Cohen Journal: J Allergy Clin Immunol Date: 2018-05-17 Impact factor: 14.290